Literature DB >> 26627606

Epithelial Transforming Growth Factor-β Signaling Does Not Contribute to Liver Fibrosis but Protects Mice From Cholangiocarcinoma.

Xueru Mu1, Jean-Philippe Pradere2, Silvia Affò2, Dianne H Dapito3, Richard Friedman4, Jay H Lefkovitch5, Robert F Schwabe6.   

Abstract

BACKGROUND & AIMS: Transforming growth factor-β (TGFβ) exerts key functions in fibrogenic cells, promoting fibrosis development in the liver and other organs. In contrast, the functions of TGFβ in liver epithelial cells are not well understood, despite their high level of responsiveness to TGFβ. We sought to determine the contribution of epithelial TGFβ signaling to hepatic fibrogenesis and carcinogenesis.
METHODS: TGFβ signaling in liver epithelial cells was inhibited by albumin-Cre-, K19-CreERT-, Prom1-CreERT2-, or AAV8-TBG-Cre-mediated deletion of the floxed TGFβ receptor II gene (Tgfbr2). Liver fibrosis was induced by carbon tetrachloride, bile duct ligation, or disruption of the multidrug-resistance transporter 2 gene (Mdr2). Hepatocarcinogenesis was induced by diethylnitrosamine or hepatic deletion of PTEN.
RESULTS: Deletion of Tgfbr2 from liver epithelial cells did not alter liver injury, toxin-induced or biliary fibrosis, or diethylnitrosamine-induced hepatocarcinogenesis. In contrast, epithelial deletion of Tgfbr2 promoted tumorigenesis and reduced survival of mice with concomitant hepatic deletion of Pten, accompanied by an increase in tumor number and a shift from hepatocellular carcinoma to cholangiocarcinoma. Surprisingly, both hepatocyte- and cholangiocyte-specific deletion of Pten and Tgfbr2 promoted the development of cholangiocarcinoma, but with different latencies. The prolonged latency and the presence of hepatocyte-derived cholangiocytes after AAV8-TBG-Cre-mediated deletion of Tgfbr2 and Pten indicated that cholangiocarcinoma might arise from hepatocyte-derived cholangiocytes in this model. Pten deletion resulted in up-regulation of Tgfbr2, and deletion of Tgfbr2 increased cholangiocyte but not hepatocyte proliferation, indicating that the main function of epithelial TGFBR2 is to restrict cholangiocyte proliferation.
CONCLUSIONS: Epithelial TGFβ signaling does not contribute to the development of liver fibrosis or formation of hepatocellular carcinomas in mice, but restricts cholangiocyte proliferation to prevent cholangiocarcinoma development, regardless of its cellular origin.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Liver Cancer; Mouse Model; Signal Transduction; TGFβ

Mesh:

Substances:

Year:  2015        PMID: 26627606      PMCID: PMC6490681          DOI: 10.1053/j.gastro.2015.11.039

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

1.  Liver cancer: TGF-β and cholangiocarcinoma.

Authors:  Gillian Patman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-16       Impact factor: 46.802

Review 2.  Current strategies to generate mature human induced pluripotent stem cells derived cholangiocytes and future applications.

Authors:  Eduardo Cervantes-Alvarez; Yang Wang; Alexandra Collin de l'Hortet; Jorge Guzman-Lepe; Jiye Zhu; Kazuki Takeishi
Journal:  Organogenesis       Date:  2017-01-05       Impact factor: 2.500

3.  The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?

Authors:  Isabel Fabregat; Gianluigi Giannelli
Journal:  Hepat Oncol       Date:  2017-07-06

4.  Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

Authors:  Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica
Journal:  Am J Pathol       Date:  2017-03-15       Impact factor: 4.307

5.  A novel role of hepatic epithelial transforming growth factor-β signaling in cholangiocarcinogenesis.

Authors:  Man Liu; Myth T S Mok; Alfred S L Cheng
Journal:  Ann Transl Med       Date:  2016-03

6.  TGFβ signaling: a friend or a foe to hepatic fibrosis and tumorigenesis.

Authors:  Dragana Kopanja; Pradip Raychaudhuri
Journal:  Ann Transl Med       Date:  2016-03

7.  MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis.

Authors:  Jorge Matias Caviglia; Jun Yan; Myoung-Kuk Jang; Geum-Youn Gwak; Silvia Affo; Lexing Yu; Peter Olinga; Richard A Friedman; Xin Chen; Robert F Schwabe
Journal:  Hepatology       Date:  2018-01-18       Impact factor: 17.425

8.  PTPN3 acts as a tumor suppressor and boosts TGF-β signaling independent of its phosphatase activity.

Authors:  Bo Yuan; Jinquan Liu; Jin Cao; Yi Yu; Hanchenxi Zhang; Fei Wang; Yezhang Zhu; Mu Xiao; Sisi Liu; Youqiong Ye; Le Ma; Dewei Xu; Ningyi Xu; Yi Li; Bin Zhao; Pinglong Xu; Jianping Jin; Jianming Xu; Xi Chen; Li Shen; Xia Lin; Xin-Hua Feng
Journal:  EMBO J       Date:  2019-06-14       Impact factor: 11.598

9.  Downregulation of microRNA-193-3p inhibits the progression of intrahepatic cholangiocarcinoma cells by upregulating TGFBR3.

Authors:  Yu-Long Han; Jia-Jun Yin; Jian-Jun Cong
Journal:  Exp Ther Med       Date:  2018-03-14       Impact factor: 2.447

10.  HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis.

Authors:  Celine Hernandez; Peter Huebener; Jean-Philippe Pradere; Daniel J Antoine; Richard A Friedman; Robert F Schwabe
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.